Roche/AbbVie’s cancer drug venetoclax, which is set to become standard of care in chronic lympocytic leukaemia, could further improve prognosis earlier in the disease according to a UK expe
A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing it significantly reduces risk of progression in CLL compared w
